Fineline Cube

Follow:
14409 Articles
UCB's Bimzelx Receives US FDA Approval for Moderate to Severe Hidradenitis Suppurativa
CompanyDrug

UCB’s Bimzelx Receives US FDA Approval for Moderate to Severe Hidradenitis Suppurativa

Alloy Therapeutics Partners with Takeda on iPSC-Derived CAR-T and CAR-NK Therapies
CompanyDeals

Alloy Therapeutics Partners with Takeda on iPSC-Derived CAR-T and CAR-NK Therapies

BeiGene Reaches Patent Settlement with MSN Pharmaceuticals for Brukinsa
Legal / IP

BeiGene Reaches Patent Settlement with MSN Pharmaceuticals for Brukinsa

Laekna and Eli Lilly & Co. Enter Clinical Cooperation to Advance Obesity Treatment LAE102
CompanyDeals

Laekna and Eli Lilly & Co. Enter Clinical Cooperation to Advance Obesity Treatment LAE102

GSK's Linerixibat Demonstrates Efficacy in Phase III GLISTEN Study for Cholestatic Pruritus
CompanyDrug

GSK’s Linerixibat Demonstrates Efficacy in Phase III GLISTEN Study for Cholestatic Pruritus

Astellas Pharma's Izervay sNDA for Geographic Atrophy Receives FDA Complete Response Letter
CompanyDrug

Astellas Pharma’s Izervay sNDA for Geographic Atrophy Receives FDA Complete Response Letter

Bayer AG Secures Exclusive Rights to Cytokinetics' Aficamten in Japan
CompanyDeals

Bayer AG Secures Exclusive Rights to Cytokinetics’ Aficamten in Japan

Merck Announces Positive Topline Results from Phase III Subcutaneous Keytruda Trial
CompanyDrug

MSD Announces Positive Topline Results from Phase III Subcutaneous Keytruda Trial

Servier and Dana-Farber Launch SHINEDoc Program, Enroll First PhD Student
CompanyDeals

Servier and Dana-Farber Launch SHINEDoc Program, Enroll First PhD Student

New Horizon Health Registers Three Medical Devices in Hong Kong's Department of Health
CompanyMedical Device

New Horizon Health Registers Three Medical Devices in Hong Kong’s Department of Health

NMPA Launches 'Medical Service Price Items' Column with Comprehensive Sub-Sections
Policy / Regulatory

NMPA Launches ‘Medical Service Price Items’ Column with Comprehensive Sub-Sections

Brii Biosciences' Elebsiran Shows Promising Results in Phase II ENSURE Study for Chronic HBV
CompanyDrug

Brii Biosciences’ Elebsiran Shows Promising Results in Phase II ENSURE Study for Chronic HBV